Drugs / Trichostatin A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03838926 | Sep 2018 → Dec 2027 expected | refractory hematologic cancer | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07065773 | May 2025 → Sep 2026 overdue | fungal infection of the toenail | Vanda Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trichostatin A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07065773 ↗ |
| Known as | TSA | “The current study aims to evaluate Trichostatin A (TSA), a presumptive radiomitigative molecule, in a rat model of combined radiation and wound injury (CRWI).” PMID 40758573 ↗ Aug 2025 |
| Route | Intravenous | “Intravenous Infusion” NCT03838926 ↗ |